The National Institutes for Health has awarded a $3 million grant to PGXL to conduct clinical trials of PerMIT:Warfarin, a software that is designed to help physicians incorporate genetic information into the treatment of their patients.

Beginning approximately in January, PerMIT will be used in carefully controlled clinical settings, in a study designed to prove (or disprove) that it decreases adverse drug reactions and reduces the time it takes to get a patient to the desired INR.

You can read the full press release here.